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MicrogliaCerebral amyloid angiopathy (CAA) occurs in nearly every individual with Alzheimer's disease (AD) and
Down's syndrome, and is the second largest cause of intracerebral hemorrhage. Mouse models of CAA have
demonstrated evidence for increased gliosis contributing to CAA pathology. Nearly two thirds of Americans
are overweight or obese, with little known about the effects of obesity on the brain, although increasingly
the vasculature appears to be a principle target of obesity effects on the brain. In the current study we de-
scribe for the ﬁrst time whether diet induced obesity (DIO) modulates glial reactivity, amyloid levels, and in-
ﬂammatory signaling in a mouse model of CAA. In these studies we identify surprisingly that DIO does not
signiﬁcantly increase Aβ levels, astrocyte (GFAP) or microglial (IBA-1) gliosis in the CAA mice. However,
within the hippocampal gyri a localized increase in reactive microglia were increased in the CA1 and stratum
oriens relative to CAA mice on a control diet. DIO was observed to selectively increase IL-6 in CAA mice, with
IL-1β and TNF-α not increased in CAA mice in response to DIO. Taken together, these data show that
prolonged DIO has only modest effects towards Aβ in a mouse model of CAA, but appears to elevate some lo-
calized microglial reactivity within the hippocampal gyri and selective markers of inﬂammatory signaling.
These data are consistent with the majority of the existing literature in other models of Aβ pathology,
which surprisingly show a mixed proﬁle of DIO effects towards pathological processes in mouse models of
neurodegenerative disease. The importance for considering the potential impact of ceiling effects in pathol-
ogy within mouse models of Aβ pathogenesis, and the current experimental limitations for DIO in mice to
fully replicate metabolic dysfunction present in human obesity, are discussed. This article is part of a Special
Issue entitled: Animal Models of Disease.
© 2013 Published by Elsevier B.V.1. Introduction
Despite the fact nearly two thirds of Americans are overweight or
obese, and the fact that obesity is known to contribute to multiple mor-
bidities and dysfunction of multiple tissues, relatively little is known in
terms of the effect of obesity on the brain [1,2]. Epidemiological and
cross sectional studies, while not uniform, suggest that presence of obe-
sity increases the incidence of numerous neurodegenerative conditions
including Alzheimer's disease (AD), vascular dementia, and cerebral
stroke [2–7]. The presence of prolonged obesity, starting in midlife, isl Models of Disease.
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sevier B.V.particularly linked to the development of neurodegenerative disorders
such as AD [8–13]. Despite such advances, very little is known in terms
of the potential mechanisms by which obesity potentially promotes
the development of neurodegenerative diseases, or which speciﬁc neu-
ropathological features may potentially be exacerbated by the presence
of obesity.
A large and robust number of publications involving ﬁndings from
rodent studies have been insightful in understanding themolecular un-
derpinnings of obesity, and the metabolic complications of obesity
[14–23]. While the impact of obesity on multiple tissues of the body
are well established in human and rodent studies (muscular, hepatic,
cardiac, nephritic systems), relatively little is known in terms of how
obesity impacts the central nervous system. In particular, there is a pau-
city of data on the effects of diet induced obesity (DIO) asmodulators of
speciﬁc neuropathological processes in established mouse models of
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mechanistic understanding as to if, and how, obesity modulates neuro-
degenerative processes involved in diseases such as AD.
Cerebral amyloid angiopathy (CAA) occurs in nearly all cases of
Alzheimer's disease (AD), Down's syndrome, and is the second leading
cause of intracerebral hemorrhage [24–28]. CAA is caused by the accu-
mulation of amyloid within the cerebrovasculature, and is associated
with numerous alterations relevant to AD and other neurodegenerative
conditions including neuroinﬂammation, oxidative stress, and gliosis.
No studies to date have examined the impact of DIO towards CAA. In
the current study, we examined the effects of prolonged DIO towards
multiple neuropathological processes in an established CAA mouse
model [29–31].
Taken together, our data demonstrate that prolonged DIO does not
increase gross measures of Aβ levels, inﬂammatory signaling, or glial re-
activity. Localized changes in microglial reactivity, a selective elevation
in IL-6, and decrease in soluble Aβ40 levels were observed in CAA mice
in response to DIO. The lack of robust DIO effects is surprisingly consis-
tent with a number of studies in the literature [32–36], and points to a
need to carefully consider the current experimental limitations in most
models of obesity and neurodegeration when studying the effects of
DIO on the brain. The potential for ceiling effects in pathology, and lim-
ited levels of metabolic dysfunction following DIO in mice, and other
experimental limitations are discussed in terms of understanding the
ability of obesity to modulate neurodegenerative disease in the brain.
2. Materials and methods
2.1. Animals and dietary treatments
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Pennington Biomedical Research Center.
Male and female C57BL/6 mice (“Control”; Charles River Laboratories)
and male and female Tg-SwDI (“CAA”) mice were studied. The TgSwDI
mouse was generated as described previously [29]. The CAA and corre-
sponding control mice were maintained and genotyped as described
previously [29–31,37]. Brieﬂy, the transgenic mouse model expressed
the human AβPP770 isoform including the Swedish, Dutch and Iowa
mutations under the Thy-1 promoter. Both genotypes were randomly
divided and assigned to either a high fat diet (HFD; D12492, Research
Diets) or control diet (CD; D12450B) at 2–3 months of age. The HFD
provided 60% kcals from fat while the CD provided 10% kcal from fat.
The CD was developed as an appropriate, balanced control to the HFD:
both contained the necessary mineral and vitamin mixes, 20% kcal
from protein and the fat source was soybean oil and lard. These diets
were administered for 9–11 months.Micewere housed in standard cag-
ingwith a 12:12 light/dark cycle and ad libitum access towater and their
respective diet unless otherwise noted. Total body fat contentwasmea-
sured via nuclear magnetic resonance (NMR) spectroscopy (Minispec,
Brucker Optics, Billerica, MA).
2.2. Immunohistochemistry
The formalin-perfusedmouse brain tissues were kept in formalin for
24–48 hours and then processed for parafﬁn embedding. Samples were
sectioned at 5 μm. For immunohistochemistry staining, parafﬁnwas re-
moved by washing slides three times in xylenes, tissue was re-hydrated
in a series of alcohol washes (100%, 95%, 70%, and 50%), and then tissue
was treated for heat-mediated antigen retrieval. Slides were washed,
blocked in 10% serum and incubated overnight with primary antibody
anti-collagen IV (Cat. #: ab6586, Abcam, Cambridge, MA, USA) in 3%
serum. The next day slides were washed, incubated with biotinylated
secondary antibody (Vector, Burlingame, CA, USA), and developed
using DAB Peroxidase Substrate Kit (Vector). For double labeling, the
slides were re-blocked again in 10% serum and incubated overnight
with primary antibody anti-IBA-1(Cat. #: 019-19741, Wako, Osaka,Japan) or anti-GFAP (Cat. #: ab48050, Abcam) in 3% serum. The next
day slides were washed, incubated with biotinylated secondary anti-
body, and developed using VIP Peroxidase Substrate Kit (Vector). Slides
were scanned using a Hamamatsu NanoZoomer Digital Slide Scanning
System (Hamamatsu City, Japan) at 20× magniﬁcation.
2.3. RT-PCR
RT-PCR experiments were performed as done previously by our lab-
oratory [38]. Total RNA from 30 mg mouse brain was isolated using
RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer's in-
structionswithminormodiﬁcations. The corresponding cDNAwasmade
from2 μg of extracted total RNAbyM-MuLV transcriptase (NewEngland
Biolabs, Ipswich, MA) using 20 μL of the reverse transcription system
according to the manufacturer's instructions. For quantitative real-time
PCR (qPCR) analysis, aliquots of cDNA were subjected to qPCR in 20 μl
of 1×Brilliant II QPCR & QRT-PCR Reagents (Agilent Technologies,
Santa Clara, CA), 1× primers and TaqMan probe (6-FAM/ZEN/IBFQ
mode) and 10 ng of cDNA. Primers and probes for TNF-α, IL-1β, IL-6
and Gapdhwere ordered through the PrimeTime Pre-designed qPCR As-
says system of Integrated DNA Technologies (IDT, Coralville, IA). Each
sample was loaded in triplicate, negative and positive controls were in-
cluded. Ampliﬁcation of Gadph was used as an internal reference gene.
PCR ampliﬁcations were performed as follows: 50 °C for 2 minutes,
95 °C for 15 minutes, and 40 cycles each with 95 °C for 15 seconds
and 60 °C for 45 seconds using an ABI PRISM 7000 sequence detector
according to themanufacturer's instructions (Applied Biosystems, Foster
City, CA). For data analysis, the ΔΔCt method was used. Relative mRNA
expression of each gene was expressed as the mean and STD of 6 inde-
pendent total RNA extractions and real-time PCR analyses.
2.4. Western blotting
Protein lysates frommouse brainweremade inRIPAbuffer using a tis-
sue homogenizer and the amount of protein in lysates was estimated
using BCA reagent (Thermo Fisher Scientiﬁc, Rockford, IL, USA). Protein
samples were analyzed by SDS-PAGE and then transferred onto a nitro-
cellulose membrane. The membrane was then probed with antibodies
anti-IBA1, GFAP as described previously and β-actin (Cat. #: sc-47778,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). All electrophoresis
and immunoblotting reagentswere purchased fromBio-Rad Laboratories
(Hercules, CA, USA). TheHRP-conjugated secondary antibodieswere pur-
chased from the Jackson ImmunoResearch Laboratories, Inc. (WestGrove,
PA, USA).
2.5. Aβ analysis
The amount of PBS and SDS soluble A was quantiﬁed as outlined
previously in numerous studies from our laboratories [39–42].
2.6. Statistical analysis
Statistical signiﬁcance between two groups was determined using a
paired t-test. All data are shown as mean±standard error of measure-
ment. For all other analyses, statistical signiﬁcance was determined by
ANOVA followed by Fisher's least signiﬁcant difference post hoc test.
Pb0.05 was considered statistically signiﬁcant (labeled as *).
3. Results
Placement of CAA and controlmice on aDIO resulted in the predicted
increase in both body weight and adiposity (Fig. 1), as compared to
maintaining animals on a control diet (CD). It is important to point out
that the current study differed from our recent publication examining
the effects of DIO on adiposity in CAA mice [43], in the fact that the
diet duration in the current study was nearly 2 times longer duration,
Fig. 1. Body weights and body fat following diet induced obesity. (A) Control HFD mice
(C-HFD) were signiﬁcantly heavier than all other groups (pb0.05) while CAA control
diet (CAA-CD) mice weighed signiﬁcantly less than all other groups (pb0.05). (B) Body
fat as measured by NMR revealed increased total body fat (pb0.05) for both groups fed
the HFD. The CAA-CD mice had less fat compared to all other groups (pb0.05).
Fig. 2. Effects of the diet induced obesity on the gross inﬂammatory signaling pathway
in mouse striatum. The mRNA level of TNF-α (A), IL-1 (B) and IL-6 (C) in mouse brain
was examined. HFD exposure selectively increased IL-6 in CAA mice (pb0.05).
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a mix of male/female mice). We next analyzed the ability of DIO to alter
the levels of Aβ40 and Aβ42. As anticipated CAA mice exhibited signiﬁ-
cant increases in both Aβ40 and Aβ42 (Table 1), as compared to control
mice. Prolonged DIO did not increase the levels of in the Aβ40/Aβ42 in
either the soluble (PBS) or insoluble (SDS) fractions (Table 1). Surpris-
ingly, prolonged DIO did signiﬁcantly decrease the levels of soluble
Aβ40 in both CAA andWT mice (Table 1).
Next we analyzed the effects of DIO towards gross inﬂammatory
signaling in CAAmice. Interestingly, prolonged DIO exposure selectively
increased IL-6 in CAA mice (Fig. 2), and curiously selectively decreased
TNF-α in control mice (Fig. 2). No signiﬁcant change in IL-1β was
observed in response to DIO (Fig. 2).
We next analyzed the impact of DIO towards the levels of microglial
and astrocyte gliosis in CAAmice. As expected, CAAmice exhibited a sig-
niﬁcant increase in both IBA-1 and GFAP levels as compared to control
mice (Fig. 3); consistent with elevated levels of microglial and astrocyte
reactivity, respectively. DIO did not signiﬁcantly alter the gross levels of
either IBA-1 or GFAP in CAA mice as measured using Western blot anal-
ysis (Fig. 3). While gross levels of GFAP and IBA-1 were not altered by
DIO, we next sought to elucidate if any change in the level of these
markers could be detectedusing immunohistochemistry. In these studies
we observed that, consistent with our Western blot analysis no signiﬁ-
cant change in GFAP immuoreactivity was observed in response to DIO
(Fig. 4). An apparent increase in the number of IBA-1 labeled, andTable 1
Dietary induced obesity effects on Aβ levels in the context of a mouse model of cerebral
amyloid angiopathy.
PBS SDS
Aβ40 Aβ42 Aβ40 Aβ42
CAA control diet 202±37 1,006±168 92,040±8,216 12,399±832
CAA high fat diet 98±41⁎ 746±205 84,564±7,358 10,251±1,050
WT control diet 70±13 497±125 1,091±62 10,892±518
WT high fat diet 12±12⁎ 542±70 862±46⁎ 11,847±539
Data are expressed as mean pmol/g tissue±SEM with 6 mice per group.
⁎ pb0.05 compared to control diet.apparently activated microglia, were observed in stratum oriens and
CA1 of the hippocampal gyri of CAA mice(Fig. 5).
4. Discussion
Our results indicate that DIO does not increase the gross Aβ levels in
either soluble or insoluble fractions of CAA mice. These data are consis-
tentwith previous studies which identiﬁed that DIO inmousemodels of
Aβ neurodegeneration do not alter the gross levels of Aβ [33,35]. Inter-
estingly, studies which combine obesity with hypercholesterolemia are
known to more consistently increase Aβ pathology in mice [44–46].
Taken together, these data suggest that more than just obesity may be
required to consistently alter gross levels of Aβ levels in mice. These ob-
servations are particularly important when considering the preclinical
use of mice for the study of obesity–Aβ interactions. For example, it is
well known thatmousemodels of DIO donot recapitulate the pleotropic
array of metabolic syndrome observed in obese humans. For example,
obesity in humans is accompanied by the development of metabolic
syndrome [47–49] including the presence of hypercholesterolemia, dia-
betes, hyperlipidemia, atherosclerosis, and hypertension [48]. In mice,
Fig. 3. Effects of the diet induced obesity on astrocyte andmicroglial reactivity.Diet induced
obesity did not signiﬁcantly alter the gross protein levels of either astrocyte (GFAP) or
microglial (IBA-1) reactivity. (A) Western-blot result of GFAP and IBA1, β-actin was used
as the loading control. Relative protein level of GFAP (B) and IBA1 (C) in mouse brain as
compared to the control control-diet (C-CD) mice.
Fig. 4. Diet induced obesity did not signiﬁcantly alter immunoreactivity and distribution
of GFAP in the hippocampus of CAAmice. The levels of astrocyte reactivityweremeasured
in the brain using GFAP immunoreactivity (purple) and co-localized with cerebral blood
vessels using collagen IV immunoreactivity (brown).
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that do are only modestly elevated (insulin resistance, hyperlipidemia).
For these reasons, the preclinical studies of DIO effects on brain neuro-
pathology should include a combination approach in which obesity is
accompanied by hypercholesterolemia or other cardiovascular disease
risk factor. Similarly, studies have not elucidated between the effects
of increased dietary fat consumption and increased levels of adiposity.
Given that shorter durations of DIO have been shown to signiﬁcantly
modify cognition and brain pathology, studies using pair feeding
(where equal caloric intake between control diet and high fat diet is ad-
ministered) need to be conducted to distinguish between the effects of
increased dietary fat and increased adiposity on the brain. Despite the
experimental differences between mice and human DIO studies, it ap-
pears that the vasculature is a key target of obesity induced effects on
the various tissues of the body [50–52]. Most studies to date have fo-
cused on the effects of obesity on the vasculature of the heart and pe-
ripheral organs, although it is highlight likely cerebrovasculature will
be a principle target of DIO effects on the brain.
Studies are needed in mice to identify which aspects of Aβ regulation
(synthesis, processing, degradation, oligomerization, deposition) are al-
tered by obesity in humans and clinically relevant mouse models. In the
current study we observed a surprising ﬁnding, whereby the levels of
Aβ40within the soluble fractionwere consistently decreased in responseto prolonged DIO. Currently, little to nothing is known in terms of the po-
tential effects of obesity on regulatory Aβ enzymes such as BACE and
secretase, nor have studies identiﬁed if obesity meaningfully changes
the rates/levels of Aβ assembly and deposition. It is important to point
out that these studies were conducted following prolonged DIO, and
the CAA mice at this age are known to have near maximal levels of Aβ.
These studies raise the likelihood of ceiling effects (in terms of potentially
maximal Aβ levels/changes) being an important consideration in the de-
signing of future studies looking at the ability of DIO to modulate Aβ
Fig. 5. Effects of diet induced obesity on the immuoreactivity and distribution of IBA1 in the
hippocampus of CAA mice. The levels of microglial reactivity were measured in the brain
using IBA-1 immunoreactivity (purple) and co-localized with cerebral blood vessels using
collagen IV immunoreactivity (brown).
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(time points, diet duration, Aβ model) such that there is signiﬁcant
room in Aβ levels to identify the ability of DIO to increase or decrease
Aβ levels in the brain. Similarly, studies need to incorporate pair feeding
studies, so that the differential effects of increased dietary fat consump-
tion and increased adiposity towards Aβ can be quantiﬁed.
Additional concerns for studies of DIO effects on the brain include the
fact that there is little consistency in the types of diets used, the duration
of diets, the control diets used for themajority of studies in the literature
(Table 2). The importance of control diets utilized is critical as the use of
chow diet as controls in DIO studies does not allow for the control of thetypes of macronutrients utilized (source, quality, etc.). These differences
make a huge difference in terms of experimental outcomes and affect the
interpretation of whether DIO is capable of modulating speciﬁc aspects
of AD related pathogenesis. It is well established that the different
mouse strains exhibit considerable variability in regards to their suscep-
tibility to DIO [33–36]. Additionally, evenwithin strain there is known to
be considerable heterogeneity in body weight gain following DIO that
appears to be due to genetic inﬂuences [61–63]. While traditionally,
these variances have been the focus of understanding the causes of obe-
sity, they have considerable inﬂuence on howmouse studies are used to
study the consequences of obesity on multiple tissues, including the
brain. For example, recent studies have demonstrated that increases in
APP occur in response to obesity in both brain and adipose tissue
[55–64], with decreases in obesity contributing to lower APP levels
[65]. But these studies did not share signiﬁcant overlap in their design,
making it difﬁcult to understand what is truly occurring in terms of
DIO effects on APP levels.
Similar to Aβ, we believe that the limited effects of prolongedDIO to-
wards gross inﬂammatory signaling markers and glial reactivity in CAA
mice is also due in large part to a ceiling effect. Interestingly, in the cur-
rent study DIO selectively increased IL-6 in CAAmice, through an as yet
unknown mechanism. These studies suggest that prolonged DIO does
not activate a broad spectrum of pro-inﬂammatory components in the
brains of CAA mice. Previous studies from our laboratory and others
have ﬁrmly established the ability of DIO tomodulate both glial reactiv-
ity and inﬂammatory signaling in the brain [55,66–70]. It is highly likely
that the modulation of these two aspects of brain homeostasis contrib-
utes to the mechanism by which DIO modulates brain pathology and
brain function, with studies currently underway in our laboratory to es-
tablish this experimentally in multiple mouse models of Aβ pathogene-
sis. Both microglia and astrocytes are key to the neurovascular unit,
raising the potential for DIOmodulatingneurovascular unit homeostasis
[71–73] and potentially serve as the basis for DIO increasing susceptibil-
ity to neurodegenerative conditions such as Alzheimer's disease [74,75].
It is important to point out that in humans and rodent studies, in-
creases in visceral adiposity are preferentially linked to the morbidities
and mortality associated with obesity [76–78]. The ability of visceral ad-
iposity to preferentiallymediate the negative effects of DIO appears to be
due to both the fact it is biochemically distinct from visceral adiposity, as
well as the fact it is near vital internal organs of thebody. Establishing the
speciﬁc role of different adipose depots inmediating the negative effects
of DIO on the brain is a critical area of future research. Similarly, it is well
established that gastric surgery in humans and rodents (gastric sleeve,
gastric bypass, roux en y) has signiﬁcant beneﬁcial effects on mobidity
and mortality [79–82]. Interestingly, these beneﬁts often occur before
signiﬁcantweight loss has occurred, and in individualswho remainmor-
bidly obese. It is presumed these rapid beneﬁcial effects aremediated by
changes in gut hormones such as GLP-1, although it remains to be deter-
mined what beneﬁcial effects of gastric surgery are on Aβ pathogenesis
and other aspects of neurodegenerative disease.
Adipose tissue is the largest endocrine tissue inmost Americans, and
the adipokines secreted by adipose tissue almost certainly contribute to
brain homeostasis. Understanding the inﬂuence of adipokines like leptin
on brain homeostasis fairly limited to date. Interestingly, studies are
showing complex roles for these adipokines in regulating Aβ processing
andAβ levels [2,83–85]. Understanding theeffects of physiological levels
of adipokines and their targets in the brain, as related to neurodegener-
ative disease, is another crucial area of research. Db/Db and Ob/Ob mice
have been useful in understanding adipose biology and adiposemodula-
tion of other tissues of the body, in particular the role of leptin signaling
in different aspects of biology and pathological processes [14,20]. Studies
involving crossing Ob/Ob diabetic mice with mouse models of Aβ pa-
thology have demonstrated evidence for accelerated neurodegeneration
and cognitive impairment [86]. It is important to point out that these
previous studies involve relatively acute experimental endpoints (ani-
mals less than 6 months old) because of the severity of obesity and
Table 2
Diet induced obesity and mouse brain functions.
Diet Duration Mouse Strain End Point & Results Ref.
60%-HFD, 10%-CD 16 weeks C57BL/6 increased reactive oxygen species (ROS); decreased cognition [43]
60%-HFD, 5%-CD 16 weeks C57BL/6 increased IR, ROS; no AD histopathology, no increase in Aβ or phospho-tau,
no impairments in IGF signaling or acetylcholine homeostasis
[33]
10% sucrose in water 25 weeks B6C3-Tg(APPswe, PSEN1dE9)85Dbo/J Metabolic dysfunction, memory impairment, increased apoE and aggregation of
Aβ in the brain
[34]
40%-WD, 10%-CD 4 weeks APPswe/PS1M146V; PS1M146V; C57BL/6 increased cerebral ROS, alterations in brain Aβ [36]
60%-HFD 16 weeks C57BL/6 impairment of fear-conditioning test [53]
60%-HFD, 10%-CD 20 weeks APPSwe/Ind metabolic dysfunction; decreased cognition [54]
21.2%-HFD, 5.5%-CD 22 weeks C57BL/6 increased pro-inﬂammatory factors and APP expression in brains and fat tissues [55]
55% -HFD 8 weeks WT, PSEN1, APP/PSEN1 AD increases body weight gain, glucose intolerance and insulin resistance induced by
HFD in mice
[56]
60%-HFD 20 weeks C57BL/6 J, MC4R−/−, Tie2-GFP enhanced GFAP-immunoreactivity in the medial preoptic, paraventricular and
dorsomedial nuclei of the hypothalamus.
[57]
60%-HFD 22 weeks C57BL/6 impaired hippocampus-dependent spatial memory, alteration in the expression of
corresponding genes
[58]
58%-HFD, 10.5%-CD 12 weeks C57BL/6 promotion of negative emotional states and depressive-like symptomology [59]
45%-HFD, 10%-CD 14 weeks C57BL/6 HFD selectively protects against the effects of chronic social stress in the mouse [60]
1461L. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 1456–1462extreme insulin resistance. The magnitude of metabolic disturbances
and obesity appear to limit the use of this model to study obesity medi-
ated effects on the brain, and make it difﬁcult to discern whether the
effects on the brain are a byproduct of amousewith amyriad ofmorbid-
ities and short life span.
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